1 Ocak 2022 Dergi makalesi Açık Erişim

Arisoy, Mustafa; Saydam, Mehtap; Dolaksiz, Yasemin Ekin; Talay, Cagri; Saglam, Onursal; Demiray, Gokce; Kurtoglu, Emel Dogan

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/254613</identifier>
  <creators>
    <creator>
      <creatorName>Arisoy, Mustafa</creatorName>
      <givenName>Mustafa</givenName>
      <familyName>Arisoy</familyName>
      <affiliation>Drogsan Pharmaceut, 1370 St, 7, TR-06520 Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Saydam, Mehtap</creatorName>
      <givenName>Mehtap</givenName>
      <familyName>Saydam</familyName>
    </creator>
    <creator>
      <creatorName>Dolaksiz, Yasemin Ekin</creatorName>
      <givenName>Yasemin Ekin</givenName>
      <familyName>Dolaksiz</familyName>
      <affiliation>Drogsan Pharmaceut, 1370 St, 7, TR-06520 Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Talay, Cagri</creatorName>
      <givenName>Cagri</givenName>
      <familyName>Talay</familyName>
      <affiliation>Drogsan Pharmaceut, 1370 St, 7, TR-06520 Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Saglam, Onursal</creatorName>
      <givenName>Onursal</givenName>
      <familyName>Saglam</familyName>
      <affiliation>Novagenix Bioanalyt Drug R&amp;D Ctr, Ozal Ave 664, TR-06970 Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Demiray, Gokce</creatorName>
      <givenName>Gokce</givenName>
      <familyName>Demiray</familyName>
      <affiliation>Novagenix Bioanalyt Drug R&amp;D Ctr, Ozal Ave 664, TR-06970 Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Kurtoglu, Emel Dogan</creatorName>
      <givenName>Emel Dogan</givenName>
      <familyName>Kurtoglu</familyName>
      <affiliation>Novagenix Bioanalyt Drug R&amp;D Ctr, Ozal Ave 664, TR-06970 Ankara, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>A Study To Compare Bioequivalence Approach Between Fda And Ema In A Highly Variable Drug: Pinaverium Bromide Film Tablets</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2022</publicationYear>
  <dates>
    <date dateType="Issued">2022-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/254613</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1016/j.xphs.2022.08.010</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">The aim of this study is to investigate pharmacokinetic parameters of test and reference film tablet formula-tions of a highly variable drug, pinaverium bromide, under fasting conditions and to assess their bioequiva-lence in accordance with the FDA and EMA criteria. A randomised open-label, single oral dose, three -sequence, three-period, semi-replicated, cross-over trial was conducted with 36 healthy subjects. The intra-subject variability of reference products for Cmax and AUC0-tlast was found to be more than 50%. While bio-equivalence was proven according to the FDA reference scaled average bioequivalence approach with only 36 subjects, more than 200 subjects are required to demonstrate bioequivalence in accordance with the EMA bioequivalence guideline. It is believed that the EMA bioequivalence criteria are too stringent for highly vari-able drugs whose intrasubject variability are more than 30% for both Cmax and AUC0-tlast and that in conse-quence the EMA ought to revise their bioequivalence guidelines for such drugs in the future. (c) 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.</description>
  </descriptions>
</resource>